DocMorris

DocMorris increased sales in the third quarter by 21% to CHF 343m and reached CHF 971m in the first nine months (+14%). The prescription drug business grew in Q3 by 78% to CHF 108m, active customers rose by 1.5m to 13.1m. For 2026 the company now expects sales growth of 12–15% (in local currency) and lowers the expected EBITDA loss to below CHF 10m. The share price jumped about 8% and hit a 52-week high. » More on deraktionaer.de

The Apothekerkammer Nordrhein carried out enforcement measures in the Netherlands against DocMorris for over €110,000 after the company was said to have breached final German judgments on advertising and discounts. German pharmacists had previously applied for administrative fines and achieved their enforcement in the Netherlands. DocMorris called the measure an enforcement of administrative fines, intends to appeal, and sees no impact on its operations or financial stability. » More on heise.de

The Apothekerkammer Nordrhein carried out enforcement measures in the Netherlands for €110,000 after DocMorris was said to have violated final German judgments on advertising and discounts. DocMorris described the action as enforcement of administrative fines, announced it would appeal, and stressed that it has no impact on operations or financial stability. The case is part of the years-long dispute between the online provider based in the Netherlands and German brick-and-mortar pharmacies over competitive conditions and cross-border trade. » More on finanzen.net